Table 3. Summary table of total antibody ICT.
Assay | Study | Year | Location of sample collection | Sample collection timing | Reference test assay type | Reference assay positivity cut-off | Sensitivity (%)/ specificity (%) |
---|---|---|---|---|---|---|---|
CareStart, AccessBio | Blacksell et ala [28] | 2010 | Laos and Thailand | Acute phase | IFA and/or PCR and/or culture | IFA: 4-fold rise in paired serum samples | 97.6/71.4 |
Blacksell et ala [19] | 2012 | Thailand | Acute (median 5 days of fever, IQR 3 to 7 days) and convalescent phase | STIC | IFA: an admission IgM titre of 1:12,800, and/or a 4-fold rising IgM titre in paired serum samples | 60.5/67.9 | |
ImmuneMed | Kim et ala [39] | 2013 | Korea | Unclear | Unclear | Unclear | 99.1/98.9 |
Kim et alb [40] | 2016 | Koread | Unclear | IFA IgM | 1:10 | 98.6/98.2 | |
IFA IgG | 1:40 | 97.1/97.7 | |||||
Koreae | Unclear | IFA IgM | 1:10 | 98.6/97.6 | |||
IFA IgG | 1:40 | 97.1/97.0 | |||||
Sri Lanka | Unclear | IFA | Unclear | 92.1/96.1 | |||
India | Unclear | IFA IgM | 1:10 | Sensitivity 86.0% | |||
IFA IgG | 1:40 | Sensitivity 92.0% | |||||
Stephen et alb [51] | 2016 | India | Acute and convalescent phase | IFA | 1:80 | 77.3/86.4 | |
InBios | Zhang et alb [26] | 2011 | China | Acute phase: 2 to 10 days after onset of illness | IgM and IgG antibodies detection (unclear) and PCR | Unclear | Sensitivity 90.9% |
Silpasakorn et alc [48] | 2012 | Thailand | Acute and convalescent phase | PCR & IFA | IFA: IgG 1:800 or a 4-fold increase | 66.7%/98.4 | |
PanBio | Coleman et alb [36] | 2002 | Thailand | Acute phase | IIP | 1:400 | 90.4/95.8 |
Panbio prototype | Wilkinson et alb [54] | 2003 | Thailand, Australia | Unclear | Unclear | Unclear | 96.1/93.0 |
SD Bioline Tsutsugamushi | Silpasakorn et alc [49] | 2012 | Thailand | Acute phase: median 6 days of fever (range 1–47 days); median interval between obtaining admission and convalescence phase: 13 days (range 3–32 days) | PCR & IFA | IFA: IgM or IgG IFA assay titre > 1:400 or a 4-fold increase | 66.7/98.4 |
Lee et alc [27] | 2014 | Korea | Unclear | IFA | 4-fold rise or single titre ≥ 1:160 | Sensitivity 72.6% | |
Stephen et alc [50] | 2015 | India | Acute and convalescence phase | ELISA IgM | Unclear | 91.7/90.5 | |
ELISA IgG | Unclear | 85.7/100.0 | |||||
Watthanaworawit et alc [29] | 2015 | Thailand | Median fever = 2 days (IQR: 2–3 days), and the median interval between obtaining initial acute-phase specimens and convalescent specimens was 14 days (range: 11–30 days). | PCR & IFA | ≥ 4-fold increase in IFA IgM titre, 1:25,600 | Acute samples: 20.9/74.4 | |
Paired samples: 76.7/76.7 | |||||||
In-house tests | Ching et ala [24] | 2001 | Unclear | Unclear | IFA | >1:40 | IgG: 86.0/97.0 |
IgG, IgM: 89.0/97.0 | |||||||
Cao et ala [25] | 2007 | China | Unclear | Unclear | Unclear | IgG: 94.6/98.9 | |
IgG, IgM: 98.2/98.1 |
aTotal antibody: IgG & IgM
bIgG
cIgG, IgM, IgA
dHealthy control sera
eDiseases non-scrub typhus control sera